Clinical Pharmacokinetics

, Volume 37, Supplement 2, pp 53–59 | Cite as

Effect of Omeprazole on the Metabolism of Cilostazol

  • Ajit Suri
  • Steven L. BramerEmail author
Original Research Article



In vitro results suggest that cilostazol is metabolised by cytochrome P450 (CYP) isoforms 1A2, 2D6, 3A4 and 2C19. This study was designed to evaluate the effect of concomitant administration of omeprazole (a CYP2C19 inhibitor) on the pharmacokinetics of a single 100mg oral dose of cilostazol.


This study was conducted as a single-centre, open-label, nonrandomised, 2-period, crossover pharmacokinetic trial. A single 100mg dose of cilostazol was administered orally on days 0 and 14. Oral omeprazole (40mg every day) was administered on days 7 to 18.

Study Participants

20 healthy nonsmoking male and female volunteers.

Main Outcome Measures

Serial blood samples were collected before and after cilostazol administration to characterise the pharmacokinetics of cilostazol and its metabolites.


Following omeprazole coadministration, the increases in cilostazol maximum plasma concentration (Cmax) and area under the plasma concentration-time curve at time t (AUCt) were 18% (p = 0.062) and 26% (p < 0.001), respectively. For the 2 major circulating metabolites, OPC-13015 and OPC-13213, the OPC-13015 Cmax and AUCt increased by 29 and 69%, respectively (p < 0.001). However, for OPC-13213, the Cmax and AUCt decreased by 22 and 31%, respectively (p < 0.001). The plasma protein binding of cilostazol was unaffected by coadministration of omeprazole.


Coadministration of cilostazol with omeprazole resulted in an increase in the systemic exposure of cilostazol and its active metabolite, OPC-13015, by 26 and 69%, respectively. For the other active metabolite, OPC-13213, systemic exposure decreased by 31% because of inhibition of cilostazol metabolism to this metabolite. These changes in systemic exposure were well tolerated. A dose of 50mg cilostazol twice a day should be considered during coadministration of inhibitors of CYP2C19, such as omeprazole.


High Performance Liquid Chromatography Adis International Limited Omeprazole Systemic Exposure Cilostazol 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kimura Y, Tani T, Kanbe T, et al. Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneimittelforschung 1985; 35(7A): 1144–9.PubMedGoogle Scholar
  2. 2.
    Kohriyama T, Tanaka E, Katayama S, et al. Antiplatelet therapy in patients with cerebral thrombosis at the chronic phase — assessment of its effect on coagulation and fibrinolytic parameters. Rinsho Shinkeigaku 1994; 34(8): 771–6.PubMedGoogle Scholar
  3. 3.
    Uchikawa T, Murakami T, Furukawa H. Effects of the antiplatelet agent cilostazol on peripheral vascular disease in patients with diabetes mellitus. Arzneimittelforschung 1992; 42(3): 322–4.PubMedGoogle Scholar
  4. 4.
    Okuda Y, Mizutani M, Ikegami T, et al. Hemodynamic effects of cilostazol on peripheral artery in patients with diabetic nephropathy. Arzneimittelforschung 1992; 42(4): 540–2.PubMedGoogle Scholar
  5. 5.
    Tsuchikane E, Katoh O, Sumitsuji S, et al. Impact of cilostazol on intimai proliferation following directional coronary atherectomy: a prospective randomized trial. J Am Coll Cardiol 1997; 29(2 Suppl. A): 397A.Google Scholar
  6. 6.
    Suehiro A, Sugimoto Y, Masuda H, et al. A study of the effects of cilostazol on platelet function and serum lipids in patients with diabetes mellitus. Curr Ther Res 1993; 54(5): 553–61.CrossRefGoogle Scholar
  7. 7.
    Elam MB, Heckman J, Crouse JR, et al. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arterioscler Thromb Vasc Biol 1998; 18(12): 1942–7.PubMedCrossRefGoogle Scholar
  8. 8.
    Abbas R, Chow CP, Browder NJ, et al. In vitro metabolism and interaction of cilostazol with human hepatic cytochrome P450 isoforms. Hum Exp Toxicol. In press.Google Scholar
  9. 9.
    Suri A, Forbes WP, Bramer SL. Effect of CYP3A inhibition on the metabolism of cilostazol. Clin Pharmacokinet 1999; 37 Suppl. 2: 61–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Anderson T. Omeprazole drug interaction studies. Clin Pharmacokinet 1991; 21(3): 195–212.CrossRefGoogle Scholar
  11. 11.
    Shimizu T, Osumi T, Niimi K, et al. Physico-chemical properties and stability of cilostazol. Arzneimittelforschung 1985; 35(7A): 1117–23.PubMedGoogle Scholar
  12. 12.
    Fu CJ, Tata PNV, Bramer SL. The quantitative determination of cilostazol and its metabolites simultaneously in human plasma by high performance liquid chromatography. J Chromatogr B Biomed Sci App 1999; 728(2): 251–62.CrossRefGoogle Scholar
  13. 13.
    Akiyama H, Kudo S, Shimizu T. The metabolism of a new antithrombotic and vasodilating agent, cilostazol, in rat, dog and man. Arzneimittelforschung 1985; 35(7A): 1133–40.PubMedGoogle Scholar
  14. 14.
    Akiyama H, Kudo S, Odomi M, et al. High-performance liquid chromatographic procedure for the determination of a new antithrombotic and vasodilating agent, cilostazol, in human plasma. J Chromatogr 1985; 338: 456–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Jusko WJ. Guidelines for collection and analysis of pharmacokinetic data. In: Evans WE, Schentag JJ, Jusko WJ, editors. Applied pharmacokinetics — principles of therapeutic drug monitoring. Spokane, WA: Applied Therapeutics, 1986.Google Scholar
  16. 16.
    Suri A, Forbes WP, Bramer SL. Pharmacokinetics of multiple-dose oral cilostazol in middle-aged and elderly men and women. J Clin Pharmcol 1998; 38: 144–50.Google Scholar
  17. 17.
    Rost KL, Roots I. Nonlinear kinetics after high-dose omeprazole caused by saturation of genetically variable Cyp2c19. Hepatology 1996; 23: 1491–7.PubMedCrossRefGoogle Scholar
  18. 18.
    Meyer UA. Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs. Eur J Gastroenterol Hepatol 1996; 8: S21–5.PubMedCrossRefGoogle Scholar
  19. 19.
    Soucek P, Gut I. Cytochrome P-450 in rats: structures, functions, properties and relevant human forms. Xenobiotica 1992; 22(1): 83–103.PubMedCrossRefGoogle Scholar
  20. 20.
    Bramer SL, Forbes WP. Relative bioavailability and effects of a high fat meal on single dose cilostazol pharmacokinetics. Clin Pharmacokinet 1999; 37 Suppl. 2: 13–23.PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1999

Authors and Affiliations

  1. 1.Otsuka America Pharmaceutical, Inc.RockvilleUSA

Personalised recommendations